Published: 30 Nov 2021 | Report Code: 10248264 | Pages: 123
Europe drug discovery market was valued at $14.8 billion in 2020 and will grow by 8.3% annually over 2020-2030 owing the rising demand for specialty medicines, the surge in lifestyle-oriented diseases and the advancements in technology, the growing elderly population and the rising healthcare expenses, rising expenditure on R&D, and expiration of patents. Highlighted with 36 tables and 64 figures, this 123-page report “Europe Drug Discovery Market 2020-2030 by Drug Type (Small Molecule, Biologics), Service (Medicinal, Biological, DMPK), Process, Technology, Therapeutic Area, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe drug discovery market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19). In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe drug discovery market in every aspect of the classification from perspectives of Drug Type, Service, Process, Technology, Therapeutic Area, End User, and Country. Based on Drug Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Small Molecule Drugs • Biologic Drugs Based on Service, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Medicinal Chemical Services • Biological Services • Drug Metabolism and Pharmacokinetics (DMPK) Services • Other Pharmaceutical Services Based on Process, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Target Selection • Target Validation • Hit-To-Lead Identification • Lead Optimization • Candidate Validation Based on Technology, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • High Throughput Screening • Combinatorial Chemistry • Pharmacogenomics and Pharmacogenetics • Nanotechnology • Bioanalytical Instruments • Biochips • Bioinformatics • Other Technologies Based on Therapeutic Area, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Oncology • Neurology • Infectious and Immune System Diseases • Digestive System Diseases • Cardiovascular Diseases • Diabetes • Respiratory Disease • Other Therapeutic Areas Based on End User, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Pharmaceutical Companies • Contract Research Organizations (CROs) • Research Institutes • Other End Users Geographically, the following national/local markets are fully investigated: • Germany • UK • France • Spain • Italy • Russia • Rest of Europe (further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland) For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2019-2030. The breakdown of key national markets by Drug Type, Service, and Therapeutic Area over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Key Players (this may not be a complete list and extra companies can be added upon request): Abbott Laboratories Inc. Agilent Technologies Inc. Astrazeneca plc Bayer AG Charles River Laboratories International Inc. Eli Lilly and Company F. Hoffmann-La Roche Ltd GlaxoSmithKline PLC Merck & Co. Inc. Novartis AG Pfizer Inc. Shimadzu Corp Thermo Fisher Scientific Inc. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Table Of Contents:
1 Introduction 7 1.1 Industry Definition and Research Scope 7 1.1.1 Industry Definition 7 1.1.2 Research Scope 8 1.2 Research Methodology 11 1.2.1 Overview of Market Research Methodology 11 1.2.2 Market Assumption 12 1.2.3 Secondary Data 12 1.2.4 Primary Data 12 1.2.5 Data Filtration and Model Design 13 1.2.6 Market Size/Share Estimation 14 1.2.7 Research Limitations 15 1.3 Executive Summary 16 2 Market Overview and Dynamics 19 2.1 Market Size and Forecast 19 2.1.1 Impact of COVID-19 on World Economy 20 2.1.2 Impact of COVID-19 on the Market 23 2.2 Major Growth Drivers 25 2.3 Market Restraints and Challenges 32 2.4 Emerging Opportunities and Market Trends 35 2.5 Porter’s Fiver Forces Analysis 39 3 Segmentation of Europe Market by Drug Type 43 3.1 Market Overview by Drug Type 43 3.2 Small Molecule Drugs 45 3.3 Biologic Drugs 46 4 Segmentation of Europe Market by Service 47 4.1 Market Overview by Service 47 4.2 Medicinal Chemical Services 49 4.3 Biological Services 50 4.4 Drug Metabolism and Pharmacokinetics (DMPK) Services 51 4.5 Other Pharmaceutical Services 52 5 Segmentation of Europe Market by Process 53 5.1 Market Overview by Process 53 5.2 Target Selection 55 5.3 Target Validation 56 5.4 Hit-To-Lead Identification 57 5.5 Lead Optimization 58 5.6 Candidate Validation 59 6 Segmentation of Europe Market by Technology 60 6.1 Market Overview by Technology 60 6.2 High Throughput Screening 62 6.3 Combinatorial Chemistry 63 6.4 Pharmacogenomics and Pharmacogenetics 64 6.5 Nanotechnology 65 6.6 Bioanalytical Instruments 66 6.7 Biochips 67 6.8 Bioinformatics 68 6.9 Other Technologies 69 7 Segmentation of Europe Market by Therapeutic Area 70 7.1 Market Overview by Therapeutic Area 70 7.2 Oncology 72 7.3 Neurology 73 7.4 Infectious and Immune System Diseases 74 7.5 Digestive System Diseases 75 7.6 Cardiovascular Diseases 76 7.7 Diabetes 77 7.8 Respiratory Disease 78 7.9 Other Therapeutic Areas 79 8 Segmentation of Europe Market by End User 80 8.1 Market Overview by End User 80 8.2 Pharmaceutical Companies 82 8.3 Contract Research Organizations (CROs) 83 8.4 Research Institutes 84 8.5 Other End Users 85 9 European Market 2019-2030 by Country 86 9.1 Overview of European Market 86 9.2 Germany 89 9.3 U.K. 92 9.4 France 95 9.5 Spain 97 9.6 Italy 99 9.7 Russia 101 9.8 Rest of European Market 103 10 Competitive Landscape 105 10.1 Overview of Key Vendors 105 10.2 New Product Launch, Partnership, Investment, and M&A 108 10.3 Company Profiles 109 Abbott Laboratories Inc. 109 Agilent Technologies Inc. 111 Astrazeneca plc 112 Bayer AG 113 Charles River Laboratories International Inc. 114 Eli Lilly and Company 115 F. Hoffmann-La Roche Ltd 116 GlaxoSmithKline PLC 117 Merck & Co. Inc. 118 Novartis AG 119 Pfizer Inc. 120 Shimadzu Corp 121 Thermo Fisher Scientific Inc. 122 RELATED REPORTS 123
List Of Tables: Table 1. Snapshot of Europe Drug Discovery Market in Balanced Perspective, 2019-2030 17 Table 2. Growth Rate of World GDP, 2020-2022 21 Table 3. World Top 10 Pharmaceutical Companies Based on Projected R&D Spending in 2026, $ bn 27 Table 4. World Health Spending by Region, $ bn, 2013-2020 30 Table 5. Total Number of Registered Clinical Studies Worldwide, 2010-2019 31 Table 6. Main Product Trends and Market Opportunities in Europe Drug Discovery Market 35 Table 7. Europe Drug Discovery Market by Drug Type, 2019-2030, $ mn 43 Table 8. Europe Drug Discovery Market by Service, 2019-2030, $ mn 47 Table 9. Europe Drug Discovery Market by Process, 2019-2030, $ mn 53 Table 10. Europe Drug Discovery Market by Technology, 2019-2030, $ mn 60 Table 11. Europe Drug Discovery Market by Therapeutic Area, 2019-2030, $ mn 70 Table 12. Europe Drug Discovery Market by End User, 2019-2030, $ mn 80 Table 13. Europe Drug Discovery Market by Country, 2019-2030, $ mn 88 Table 14. Germany Drug Discovery Market by Drug Type, 2019-2030, $ mn 90 Table 15. Germany Drug Discovery Market by Service, 2019-2030, $ mn 90 Table 16. Germany Drug Discovery Market by Therapeutic Area, 2019-2030, $ mn 90 Table 17. U.K. Drug Discovery Market by Drug Type, 2019-2030, $ mn 94 Table 18. U.K. Drug Discovery Market by Service, 2019-2030, $ mn 94 Table 19. U.K. Drug Discovery Market by Therapeutic Area, 2019-2030, $ mn 94 Table 20. France Drug Discovery Market by Drug Type, 2019-2030, $ mn 96 Table 21. France Drug Discovery Market by Service, 2019-2030, $ mn 96 Table 22. France Drug Discovery Market by Therapeutic Area, 2019-2030, $ mn 96 Table 23. Spain Drug Discovery Market by Drug Type, 2019-2030, $ mn 98 Table 24. Spain Drug Discovery Market by Service, 2019-2030, $ mn 98 Table 25. Spain Drug Discovery Market by Therapeutic Area, 2019-2030, $ mn 98 Table 26. Italy Drug Discovery Market by Drug Type, 2019-2030, $ mn 100 Table 27. Italy Drug Discovery Market by Service, 2019-2030, $ mn 100 Table 28. Italy Drug Discovery Market by Therapeutic Area, 2019-2030, $ mn 100 Table 29. Russia Drug Discovery Market by Drug Type, 2019-2030, $ mn 102 Table 30. Russia Drug Discovery Market by Service, 2019-2030, $ mn 102 Table 31. Russia Drug Discovery Market by Therapeutic Area, 2019-2030, $ mn 102 Table 32. Drug Discovery Market in Rest of Europe by Country, 2019-2030, $ mn 104 Table 33. Abbott Laboratories Inc.: Company Snapshot 109 Table 34. Abbott Laboratories Inc.: Business Segmentation 109 Table 35. Abbott Laboratories Inc.: Product Portfolio 110 Table 36. Abbott Laboratories Inc.: Revenue, 2018-2020, $ mn 110
List Of Figures: Figure 1. Research Method Flow Chart 11 Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14 Figure 3. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 16 Figure 4. Europe Drug Discovery Market, 2019-2030, $ mn 19 Figure 5. Impact of COVID-19 on Business 23 Figure 6. Primary Drivers and Impact Factors of Europe Drug Discovery Market 25 Figure 7. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 29 Figure 8. World Population 65 and Over, % of Total Population, 1950-2060 29 Figure 9. Primary Restraints and Impact Factors of Europe Drug Discovery Market 32 Figure 10. Investment Opportunity Analysis 36 Figure 11. Porter’s Fiver Forces Analysis of Europe Drug Discovery Market 39 Figure 12. Breakdown of Europe Drug Discovery Market by Drug Type, 2019-2030, % of Revenue 44 Figure 13. Europe Addressable Market Cap in 2021-2030 by Drug Type, Value ($ mn) and Share (%) 44 Figure 14. Europe Drug Discovery Market by Drug Type: Small Molecule Drugs, 2019-2030, $ mn 45 Figure 15. Europe Drug Discovery Market by Drug Type: Biologic Drugs, 2019-2030, $ mn 46 Figure 16. Breakdown of Europe Drug Discovery Market by Service, 2019-2030, % of Sales Revenue 48 Figure 17. Europe Addressable Market Cap in 2021-2030 by Service, Value ($ mn) and Share (%) 48 Figure 18. Europe Drug Discovery Market by Service: Medicinal Chemical Services, 2019-2030, $ mn 49 Figure 19. Europe Drug Discovery Market by Service: Biological Services, 2019-2030, $ mn 50 Figure 20. Europe Drug Discovery Market by Service: Drug Metabolism and Pharmacokinetics (DMPK) Services, 2019-2030, $ mn 51 Figure 21. Europe Drug Discovery Market by Service: Other Pharmaceutical Services, 2019-2030, $ mn 52 Figure 22. Breakdown of Europe Drug Discovery Market by Process, 2019-2030, % of Sales Revenue 54 Figure 23. Europe Addressable Market Cap in 2021-2030 by Process, Value ($ mn) and Share (%) 54 Figure 24. Europe Drug Discovery Market by Process: Target Selection, 2019-2030, $ mn 55 Figure 25. Europe Drug Discovery Market by Process: Target Validation, 2019-2030, $ mn 56 Figure 26. Europe Drug Discovery Market by Process: Hit-To-Lead Identification, 2019-2030, $ mn 57 Figure 27. Europe Drug Discovery Market by Process: Lead Optimization, 2019-2030, $ mn 58 Figure 28. Europe Drug Discovery Market by Process: Candidate Validation, 2019-2030, $ mn 59 Figure 29. Breakdown of Europe Drug Discovery Market by Technology, 2019-2030, % of Revenue 61 Figure 30. Europe Addressable Market Cap in 2021-2030 by Technology, Value ($ mn) and Share (%) 61 Figure 31. Europe Drug Discovery Market by Technology: High Throughput Screening, 2019-2030, $ mn 62 Figure 32. Europe Drug Discovery Market by Technology: Combinatorial Chemistry, 2019-2030, $ mn 63 Figure 33. Europe Drug Discovery Market by Technology: Pharmacogenomics and Pharmacogenetics, 2019-2030, $ mn 64 Figure 34. Europe Drug Discovery Market by Technology: Nanotechnology, 2019-2030, $ mn 65 Figure 35. Europe Drug Discovery Market by Technology: Bioanalytical Instruments, 2019-2030, $ mn 66 Figure 36. Europe Drug Discovery Market by Technology: Biochips, 2019-2030, $ mn 67 Figure 37. Europe Drug Discovery Market by Technology: Bioinformatics, 2019-2030, $ mn 68 Figure 38. Europe Drug Discovery Market by Technology: Other Technologies, 2019-2030, $ mn 69 Figure 39. Breakdown of Europe Drug Discovery Market by Therapeutic Area, 2019-2030, % of Revenue 71 Figure 40. Europe Addressable Market Cap in 2021-2030 by Therapeutic Area, Value ($ mn) and Share (%) 71 Figure 41. Europe Drug Discovery Market by Therapeutic Area: Oncology, 2019-2030, $ mn 72 Figure 42. Europe Drug Discovery Market by Therapeutic Area: Neurology, 2019-2030, $ mn 73 Figure 43. Europe Drug Discovery Market by Therapeutic Area: Infectious and Immune System Diseases, 2019-2030, $ mn 74 Figure 44. Europe Drug Discovery Market by Therapeutic Area: Digestive System Diseases, 2019-2030, $ mn 75 Figure 45. Europe Drug Discovery Market by Therapeutic Area: Cardiovascular Diseases, 2019-2030, $ mn 76 Figure 46. Europe Drug Discovery Market by Therapeutic Area: Diabetes, 2019-2030, $ mn 77 Figure 47. Europe Drug Discovery Market by Therapeutic Area: Respiratory Disease, 2019-2030, $ mn 78 Figure 48. Europe Drug Discovery Market by Therapeutic Area: Other Therapeutic Areas, 2019-2030, $ mn 79 Figure 49. Breakdown of Europe Drug Discovery Market by End User, 2019-2030, % of Revenue 80 Figure 50. Europe Addressable Market Cap in 2021-2030 by End User, Value ($ mn) and Share (%) 81 Figure 51. Europe Drug Discovery Market by End User: Pharmaceutical Companies, 2019-2030, $ mn 82 Figure 52. Europe Drug Discovery Market by End User: Contract Research Organizations (CROs), 2019-2030, $ mn 83 Figure 53. Europe Drug Discovery Market by End User: Research Institutes, 2019-2030, $ mn 84 Figure 54. Europe Drug Discovery Market by End User: Other End Users, 2019-2030, $ mn 85 Figure 55. Breakdown of European Drug Discovery Market by Country, 2019 and 2030, % of Revenue 87 Figure 56. Contribution to Europe 2021-2030 Cumulative Market by Country, Value ($ mn) and Share (%) 88 Figure 57. Drug Discovery Market in Germany, 2019-2030, $ mn 89 Figure 58. Drug Discovery Market in U.K., 2019-2030, $ mn 92 Figure 59. Drug Discovery Market in France, 2019-2030, $ mn 95 Figure 60. Drug Discovery Market in Spain, 2019-2030, $ mn 97 Figure 61. Drug Discovery Market in Italy, 2019-2030, $ mn 99 Figure 62. Drug Discovery Market in Russia, 2019-2030, $ mn 101 Figure 63. Drug Discovery Market in Rest of Europe, 2019-2030, $ mn 103 Figure 64. Growth Stage of Europe Drug Discovery Industry over the Forecast Period 105
Key Players (this may not be a complete list and extra companies can be added upon request): Abbott Laboratories Inc. Agilent Technologies Inc. Astrazeneca plc Bayer AG Charles River Laboratories International Inc. Eli Lilly and Company F. Hoffmann-La Roche Ltd GlaxoSmithKline PLC Merck & Co. Inc. Novartis AG Pfizer Inc. Shimadzu Corp Thermo Fisher Scientific Inc. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)